Germany’s Bayer and privately-held Kumquat Biosciences, a US biotech founded by pioneers of the KRAS pathway, have entered into an exclusive global license and collaboration to develop and ...

German pharmaceutical giant Bayer said Tuesday it had struck a deal valued at up to $1.3 billion (1.1 billion euros) with a US ...

Today’s White House MAHA Commission report is expected to pull punches on pesticide regulation as Bayer lobbies to limit ...

As long as the football is this delightful and the wins keep coming, the promotion hopes from this season are well founded. With this victory, Bayern II pull to 1st in the Regionalliga Bayern table ...

According to the Daily Telegraph’s John Percy, Newcastle hold a “strong interest” in Leicester City’s versatile attacking ...

The biggest new Premier League transfer rumours - with news from Manchester United, Chelsea, Arsenal and more.

The German pharma will license a KRAS G12D inhibitor from Kumquat Biosciences. Elsewhere, a Biohaven OCD drug missed its ...

The Oklahoma City Thunder felt slighted last season when they were left off the NBA's Christmas schedule. That won't be an ...

Whatever was behind Long’s removal, the administration is crossing into dangerous new territory in trying to pry open private ...

Out of the blue, we have the renowned expert on all things Sunderland — Chris Waddle — scratching his head at the ‘strange’ ...